Featured Research

from universities, journals, and other organizations

Fewer drugs listed on public drug plans after introduction of Canada’s common drug review but faster listing for coverage

Date:
October 24, 2011
Source:
Canadian Medical Association Journal
Summary:
The number of drugs covered by public drug plans decreased substantially after Canada's Common Drug Review was introduced in 2003, and new drugs were listed more quickly in several of the smaller provinces, a new study finds.

The number of drugs covered by public drug plans decreased substantially after Canada's Common Drug Review was introduced in 2003, and new drugs were listed more quickly in several of the smaller provinces, found a study published in CMAJ (Canadian Medical Association Journal).

Canada has 19 public drug plans, which accounted for about 39% of the forecasted $31 billion in drug-related costs in 2010. These plans cover the cost of a range of drugs prescribed to patients. Before 2003, each plan independently reviewed evidence for clinical and cost-effectiveness for new drugs under consideration for listing under drug plans. The Canada Common Drug Review, administered by the Canadian Agency for Drugs and Technologies in Health, was introduced to standardize the process, improve efficiencies by pooling resources and expertise and eliminate duplication. Quebec does not participate in the Common Drug Review.

Researchers from the University of Alberta found that the number of drugs listed for coverage decreased substantially. Participating drug plans listed between 47% and 66% of new drugs in the five years before the Common Drug Review and between 12% and 40% in the five years following. As well, the time from recommendation to be listed and actual date listed ranged from 99 to 358 days, compared with an average time-to-listing of 778 days -- more than two years -- before the Common Drug Review.

There was also significant variation between listing decisions of public drug plans and recommendations of the Common Drug Review.

"The proportion of drugs listed decreased significantly after the introduction of the Common Drug Review for all participating drug plans included in our analysis," states Dr. Dean Eurich, School of Public Health, University of Alberta, with coauthors. "Time-to-listing decreased for a number of the smaller provinces."

The authors write that several factors, including uncertainty over the clinical effectiveness of drugs submitted by pharmaceutical companies for review, may explain the decrease in the number of drugs listed for reimbursement.

"Our findings suggest that the Common Drug Review may have contributed to a streamlining of the process for reviewing drugs for certain jurisdictions," write the authors "Specifically, patients in the provinces of New Brunswick, Prince Edward Island, and Newfoundland and Labrador may have benefited with earlier access to new drugs. Any substantial gains in savings or in the efficiency of publicly funded drug plans to make listing decisions are important factors in maintaining the health and safety of Canadian patients."


Story Source:

The above story is based on materials provided by Canadian Medical Association Journal. Note: Materials may be edited for content and length.


Journal Reference:

  1. John-Michael Gamble, Daniala L. Weir, Jeffrey A. Johnson, Dean T. Eurich. Analysis of drug coverage before and after the implementation of Canada's Common Drug Review. CMAJ, 2011; DOI: 10.1503/cmaj.110670

Cite This Page:

Canadian Medical Association Journal. "Fewer drugs listed on public drug plans after introduction of Canada’s common drug review but faster listing for coverage." ScienceDaily. ScienceDaily, 24 October 2011. <www.sciencedaily.com/releases/2011/10/111024123002.htm>.
Canadian Medical Association Journal. (2011, October 24). Fewer drugs listed on public drug plans after introduction of Canada’s common drug review but faster listing for coverage. ScienceDaily. Retrieved July 23, 2014 from www.sciencedaily.com/releases/2011/10/111024123002.htm
Canadian Medical Association Journal. "Fewer drugs listed on public drug plans after introduction of Canada’s common drug review but faster listing for coverage." ScienceDaily. www.sciencedaily.com/releases/2011/10/111024123002.htm (accessed July 23, 2014).

Share This




More Health & Medicine News

Wednesday, July 23, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

Courts Conflicted Over Healthcare Law

Courts Conflicted Over Healthcare Law

AP (July 22, 2014) Two federal appeals courts issued conflicting rulings Tuesday on the legality of the federally-run healthcare exchange that operates in 36 states. (July 22) Video provided by AP
Powered by NewsLook.com
Why Do People Believe We Only Use 10 Percent Of Our Brains?

Why Do People Believe We Only Use 10 Percent Of Our Brains?

Newsy (July 22, 2014) The new sci-fi thriller "Lucy" is making people question whether we really use all our brainpower. But, as scientists have insisted for years, we do. Video provided by Newsy
Powered by NewsLook.com
Scientists Find New Way To Make Human Platelets

Scientists Find New Way To Make Human Platelets

Newsy (July 22, 2014) Boston scientists have discovered a new way to create fully functioning human platelets using a bioreactor and human stem cells. Video provided by Newsy
Powered by NewsLook.com
Gilead's $1000-a-Pill Drug Could Cure Hep C in HIV-Positive People

Gilead's $1000-a-Pill Drug Could Cure Hep C in HIV-Positive People

TheStreet (July 21, 2014) New research shows Gilead Science's drug Sovaldi helps in curing hepatitis C in those who suffer from HIV. In a medical study, the combination of Gilead's Hep C drug with anti-viral drug Ribavirin cured 76% of HIV-positive patients suffering from the most common hepatitis C strain. Hepatitis C and related complications have been a top cause of death in HIV-positive patients. Typical medication used to treat the disease, including interferon proteins, tended to react badly with HIV drugs. However, Sovaldi's %1,000-a-pill price tag could limit the number of patients able to access the treatment. TheStreet's Keris Lahiff reports from New York. Video provided by TheStreet
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:

Breaking News:
from the past week

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News



Save/Print:
Share:

Free Subscriptions


Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile


Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?


Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile: iPhone Android Web
Follow: Facebook Twitter Google+
Subscribe: RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins